Ethylene Glycol

Ethylene Glycol

SCHEMBL500121

CCCCC(CC)(CC)C(=O)O.OCCO

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.44
CYP4A11 Q02928 2/20 0.44
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
AKR1B1 P15121 1/20 0.34
NAAA Q02083 1/20 0.34
PPARG P37231 4/20 0.33
PPARD Q03181 4/20 0.33
PPARA Q07869 4/20 0.33
TSHR P16473 3/20 0.33
GPR84 Q9NQS5 3/20 0.33
HDAC11 Q96DB2 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
LMNA P02545 2/20 0.33
HSD17B10 Q99714 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
SLC22A6 Q4U2R8 1/20 0.33
SLC22A8 Q8TCC7 1/20 0.33
TLR2 O60603 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL392507 0.93 CYP4F2 (0.39) CYP4F2CYP4A11ALDH1A1AKR1B1PPARG
SCHEMBL28125208 0.93 CYP4F2 (0.39) CYP4F2CYP4A11ALDH1A1AKR1B1PPARG
Strontium SCHEMBL6277016 0.91 CYP4F2 (0.38) CYP4F2CYP4A11ALDH1A1AKR1B1PPARG
SCHEMBL6282572 0.91 CYP4F2 (0.38) CYP4F2CYP4A11ALDH1A1AKR1B1PPARG
SCHEMBL28643897 0.91 CYP4F2 (0.38) CYP4F2CYP4A11ALDH1A1AKR1B1PPARG
SCHEMBL8939717 0.91 CYP4F2 (0.38) CYP4F2CYP4A11ALDH1A1AKR1B1PPARG
SCHEMBL8921783 0.91 CYP4F2 (0.38) CYP4F2CYP4A11ALDH1A1AKR1B1PPARG
SCHEMBL5970743 0.91 CYP4F2 (0.38) CYP4F2CYP4A11ALDH1A1AKR1B1PPARG
SCHEMBL680541 0.91 CYP4F2 (0.38) CYP4F2CYP4A11ALDH1A1AKR1B1PPARG
SCHEMBL8917440 0.91 CYP4F2 (0.38) CYP4F2CYP4A11ALDH1A1AKR1B1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122055128-A Dispersion and cosmetic containing the same 信越化学工业株式会社 2026-05-15 CN disclosed
US-12491150-B2 Compound in which polyglycerol, fatty acid, and dicarboxylic acid have been esterified TAIYO KAGAKU CO., LTD. (JP) 2025-12-09 US disclosed
CN-119894485-A Water-in-oil type cosmetic 信越化学工业株式会社 2025-04-25 CN disclosed
US-20250107994-A1 COMPOUND IN WHICH POLYGLYCEROL, FATTY ACID, AND DICARBOXYLIC ACID HAVE BEEN ESTERIFIED TAIYO KAGAKU CO., LTD. (JP) 2025-04-03 US disclosed
CN-119730835-A Cosmetic containing crosslinked silicone resin and method for producing same 信越化学工业株式会社 2025-03-28 CN disclosed
CN-119497606-A Surfactant composition and cleaning agent 三洋化成工业株式会社 2025-02-21 CN disclosed
EP-4506331-A1 COMPOUND IN WHICH POLYGLYCEROL, FATTY ACID, AND DICARBOXYLIC ACID HAVE BEEN ESTERIFIED Taiyo Kagaku Co., Ltd. (JP) 2025-02-12 EP disclosed
CN-119403531-A Dispersion and cosmetic containing the same 信越化学工业株式会社 2025-02-07 CN disclosed
CN-119173248-A Active agent composition and cosmetic 信越化学工业株式会社 2024-12-20 CN disclosed
CN-119095582-A Cosmetic material 信越化学工业株式会社 2024-12-06 CN disclosed
CN-116917380-A Organopolysiloxane and cosmetic containing the same 信越化学工业株式会社 2023-10-20 CN disclosed
WO-2023181682-A1 COMPOUND IN WHICH POLYGLYCEROL, FATTY ACID, AND DICARBOXYLIC ACID HAVE BEEN ESTERIFIED 太陽化学株式会社 2023-09-28 WO disclosed
US-8105637-B2 health food and drink contains the pure plant extract, is for patients with abnormality in cerebral blood flow and metabolism of brain disorder; nutraceuticals; free of proanthocyanidins SHIMADA SHINJI (JP) 2012-01-31 US disclosed
EP-1602354-B1 Use of polyglutamic acid or its salts MEIJI SEIKA KAISHA (JP) 2008-11-05 EP disclosed
US-20080254126-A1 Composition comprising nanoparticle ginkgo biloba extract with the effect of brain function activation SHIMADA SHINJI 2008-10-16 US disclosed
EP-1604647-B1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof CHISSO CORP (JP) 2008-05-07 EP disclosed
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair MEIJI SEIKA KAISHA, LTD. (JP) 2006-07-27 US disclosed
US-20060018867-A1 Cosmetic composition and production thereof ICHIMARU PHARCOS CO., LTD 2006-01-26 US disclosed
EP-1604647-A1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof Ichimaru Pharcos Co., Ltd. (JP) 2005-12-14 EP disclosed
EP-1602354-A1 HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR Meiji Seika Kaisha, Ltd. (JP) 2005-12-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair CUTA, COL14A1, PRKDC CYP4F2 4873/4885CYP4A11 4851/4885ALDH1A1 2963/4885
US-20060018867-A1 Cosmetic composition and production thereof CUTA, PARG, TYR CYP4F2 4358/4885CYP4A11 4420/4885ALDH1A1 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.